Neurological Biomarkers Market Size, Share Report, Analysis, Trends, Growth 2032

Neurological Biomarkers Market Overview

The global Neurological Biomarkers market size accrued earnings worth approximately USD 6.12 Billion in 2023 and is predicted to gain revenue of about USD 21.11 Billion by 2032, is set to record a CAGR of nearly 13.42% over the period from 2024 to 2032.

Request Free Sample

Neurological Biomarkers Market Introduction

Neurological biomarkers are utilized for detecting the persons at the risk of having neurological ailments and some of these biomarkers are used for diagnosing the disorder, determine its progress, and estimate the disease result. In therapeutic surroundings, these biomarkers unleash information related to the effectiveness of the medicine for a particular neurological disorder as well as its side-effects. Citing an instance, uric acid is a key biomarker that helps in detecting the growth of Parkinson ailment and the need for the drug development to inhibit the growth. In addition to this, MRI-based biomarkers help in determining intensity of multiple sclerosis, spinal muscular atrophy, retinal neurodegenerative disorder, and acute ischemic strokes.

Request Free Sample

Neurological Biomarkers Market Growth Dynamics

Technological innovations in genomics, metabolomics, and proteomics are predicted to steer the growth of neurological biomarkers industry over the estimated timeframe. Apparently, large-scale occurrence of the neurological ailments due to stressful & hectic work schedule as well as work-life imbalance will drive the market trends. In addition to this, less proportion of effective diagnostics tools available in emerging countries has resulted in rise in the mortality due to neurological diseases, thereby enhancing the need for neurological biomarkers in these countries.

Furthermore, surge in the neurological disorders like Alzheimer, brain tumors, Parkinson, cerebral stroke, and epilepsy will pave a way for the industry growth over the forecasting years. Apparently, favorable government schemes as well as rise in the investment in neurological diagnostics sector has translated into market demand. Rise in the research activities pertaining to neuroscience and huge funding provided by the government agencies to promote neuro-medicine discoveries will embellish the industry expansion in the coming years.

Neurological Biomarkers Market: Report Scope

Neurological Biomarkers Market Segmentation Analysis

Product type, indication, imaging methods, services, and end user are the factors that divide the market for neurological biomarkers. The expansion within these sectors will assist in examining areas of limited growth within the industries and offer users a valuable market overview and insights to aid in making strategic decisions for identifying key market applications.

Asia Pacific Market To Accrue Huge Returns Over 2024-2032

Rise in the occurrence of neurological disorders like Alzheimer and Parkinson among the aging population has generated huge demand for the neurological biomarker, thereby spurring the market growth in the region. Apart from this, rise in the awareness pertaining to neurological diseases and a complete overhaul as well as drastic improvisations witnessed in healthcare infrastructure facilities in the countries like China will magnify the market growth in the Asia Pacific zone. Apart from China, countries like South Korea and India are projected to be the major regional revenue drivers over the next couple of years.

Key players influencing the market growth are

• Bio-Rad Laboratories, Inc.
• QIAGEN
• Alseres Pharmaceuticals, Inc.
• Abbott
• Thermo Fisher Scientific Inc.
• Acumen Pharmaceuticals
• Myriad RBM
• Athena Diagnostics
• AbaStar MDx, Inc.
• and BANYAN BIOMARKERS, INC.

The global neurological biomarkers market is segmented as follows:

By application:

• Multiple Sclerosis
• Alzheimer’s Disease
• Parkinson’s Disease
• Autism Spectrum Disorders
• Others

By type:

• Metabolomic
• Genomic
• Proteomic
• Imaging
• Others

By end-user:

• Research Organizations
• Hospital Laboratories
• Independent Clinical Diagnostic Centers
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa